| Gene symbol | APOB | Synonyms | FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48 | Type of gene | protein-coding |
| Chromosome | 2 | Map location | 2p24.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | apolipoprotein B | ||||
| GTO ID | GTC1388 |
| Trial ID | NCT01414881 |
| Disease | Familial Hypercholesterolemia |
| Altered gene | APOB |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS 301012|mipomersen sodium|Kynamro |
| Location approved | US, Mexico, Argentina, South Korea |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1 Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects |
| Year | 2011 |
| Country | United States |
| Company sponsor | Kastle Therapeutics, LLC |
| Other ID(s) | MIPO1600810 |
| Vector information | |||
|
|||
| Cohort1: mipomersen | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||